摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(N-BOC-氨甲基)苯基硼酸 | 199609-62-6

中文名称
3-(N-BOC-氨甲基)苯基硼酸
中文别名
3-(BOC-氨甲基)苯硼酸;3-(N-BOC-氨基甲基)苯基硼酸
英文名称
(3-{[(tert-butoxycarbonyl)amino]methyl}phenyl)boronic acid
英文别名
3-(N-Boc-aminomethyl)phenylboronic acid;[3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]boronic acid
3-(N-BOC-氨甲基)苯基硼酸化学式
CAS
199609-62-6
化学式
C12H18BNO4
mdl
MFCD06246052
分子量
251.09
InChiKey
YHAQUGOSDQZIMA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    188-190°C
  • 密度:
    1.15±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.04
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    78.8
  • 氢给体数:
    3
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2931900090
  • 危险类别:
    IRRITANT
  • 危险性防范说明:
    P261,P280
  • 危险性描述:
    H317

SDS

SDS:5a09cef748e258bb9b61813cce529462
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-(N-Boc-aminomethyl)phenylboronic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection

Section 3. Composition/information on ingredients.
Ingredient name: 3-(N-Boc-aminomethyl)phenylboronic acid
CAS number: 199609-62-6

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H18BO4
Molecular weight: 251.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(N-BOC-氨甲基)苯基硼酸(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloridepotassium phosphate 、 palladium 10% on activated carbon 、 氢气 、 sulfur 作用下, 以 1,4-二氧六环甲醇N,N-二甲基乙酰胺 为溶剂, 110.0~120.0 ℃ 、101.33 kPa 条件下, 反应 2.67h, 生成 tert-butyl (3-(2-(5-bromo-1-trityl-1H-indazol-3-yl)-1H-benzo[d]imidazol-4-yl)benzyl)carbamate
    参考文献:
    名称:
    [EN] INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF
    [FR] MACROCYCLES CONTENANT DE L'INDAZOLE ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
    摘要:
    公开了用于治疗各种疾病和病理的Indazole大环化合物的化学式(I)。更具体地,本发明涉及使用Indazole大环化合物或其类似物治疗由Wnt途径信号激活所特征的疾病(例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎),调节由Wnt途径信号介导的细胞事件,以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理/疾病/疾病。还提供了治疗与Wnt相关疾病状态的方法。化学式(I)
    公开号:
    WO2019241540A1
  • 作为产物:
    参考文献:
    名称:
    Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
    摘要:
    各种噻吩并嘧啶类衍生物能够选择性地抑制Src家族的酪氨酸激酶。这些化合物在治疗包括过度增殖性疾病、血液病、骨质疏松症、神经性疾病、自身免疫病、过敏/免疫性疾病或病毒感染等多种疾病中是有用的。
    公开号:
    US20060004002A1
点击查看最新优质反应信息

文献信息

  • Chemical Compounds
    申请人:Brown Alan Daniel
    公开号:US20120010182A1
    公开(公告)日:2012-01-12
    The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z 1 , R a , R b , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
    该发明涉及磺胺衍生物,其在医学上的应用,含有它们的组合物,其制备方法以及用于这些方法的中间体。 更具体地,该发明涉及公式(I)的新磺胺基Nav1.7抑制剂: 或其药学上可接受的盐,其中Z 1 ,R a ,R b ,R 1 ,R 2 ,R 3 ,R 4 和R 5 如描述中所定义。 Nav 1.7抑制剂在治疗各种疾病,特别是疼痛方面具有潜在用途。
  • [EN] AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF<br/>[FR] AZAINDAZOLES COMME MODULATEURS DE LA KINASE BTK ET LEUR UTILISATION
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2011019780A1
    公开(公告)日:2011-02-17
    Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4, are as defined herein.
    具有化学式(I)的化合物,以及其对映体、非对映异构体、药用可接受的盐,(I)可用作激酶调节剂,包括Btk调节,在此处定义了A1、A2、A3、R4。
  • [EN] SUBSTITUTED SULFONAMIDE COMPOUNDS<br/>[FR] COMPOSÉS DE SULFONAMIDE SUBSTITUÉS
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014049047A1
    公开(公告)日:2014-04-03
    The invention is concerned with the compounds of formula (I), and salts thereof, wherein X, Y, Z, R1, R2, R3, R3, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    本发明涉及公式(I)的化合物及其盐,其中X、Y、Z、R1、R2、R3、R3、R4、R5和R6在详细描述和权利要求中定义。此外,本发明还涉及制造和使用公式(I)化合物的方法,以及含有此类化合物的药物组合物。这些化合物可能对治疗由TRPA1介导的疾病和状况,如疼痛,有益。
  • [EN] BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS<br/>[FR] COMPOSÉS AMINE HÉTÉROARYLES BICYCLIQUES UTILISÉS COMME INHIBITEURS DE LA PI3K
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2016064957A1
    公开(公告)日:2016-04-28
    Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) C1, Br, I, -CN, -CH3, or -CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
    公开了Formula (I)或其盐的化合物;其中:X为N或CH;Q1为:(i) C1、Br、I、-CN、-CH3或-CF3;(ii)从吡咯基、吡唑基、咪唑基、噁唑基、噻唑基、三唑基、噁二唑基和噻二唑基中选择的5-成员杂芳基;(iii)从吡啶基、吡啶嗪基和嘧啶基中选择的6-成员杂芳基;或(iv)从吲哚基、吡咯吡啶基、吡唑吡啶基和苯并[d]噁唑基中选择的双环杂芳基;其中所述的5-成员、6-成员和双环杂芳基中的每一个都被零至1个Ra和零至1个Rb取代;R1、R2、R3、R4、R5、R6、Ra和Rb在此处被定义。还公开了使用这些化合物作为PI3K调节剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症性和自身免疫性疾病方面是有用的。
  • [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
    申请人:ALMAC DISCOVERY LTD
    公开号:WO2018020242A1
    公开(公告)日:2018-02-01
    The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    本发明涉及一种具有以下式(I)的化合物,该化合物可用作泛素特异性蛋白酶USP19活性的抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物进行治疗的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐